Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7972501 | 0.82 | PARP1 (0.41) | PARP1ACHEALDH1A1LMNA | |
| SCHEMBL19973594 | 0.82 | PARP1 (0.41) | PARP1ACHEALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL19974005 | 0.81 | PARP1 (0.40) | PARP1ACHEALDH1A1 | |
| Hydrochloric Acid SCHEMBL19974004 | 0.81 | PARP1 (0.40) | PARP1ACHEALDH1A1 | |
| Bromide SCHEMBL29540950 | 0.71 | ACHE (0.43) | ACHE | |
| Bromide SCHEMBL20554328 | 0.71 | ACHE (0.43) | ACHE | |
| SCHEMBL10587461 | 0.70 | CFD (0.42) | ACHEKDM4E | |
| SCHEMBL19973699 | 0.70 | KDM4E (0.43) | KDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL8128005 | 0.70 | NPC1 (0.51) | KDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL10586303 | 0.70 | PTGDR2 (0.49) | KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | PARP1 435/4885ACHE 1996/4885HTR4 2346/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | PARP1 435/4885ACHE 1996/4885HTR4 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.